Skip to content

    Vinati Organics

    VINATIORGANeutral
    Chemicals·16 Aug 2023
    Management Summary

    Vinati Organics faced a challenging Q1 FY24 characterized by significant inventory destocking in its flagship ATBS product, particularly within the Oil & Gas segment. Despite a 14% revenue contraction, the company maintained healthy EBITDA margins of 28%. Management remains focused on long-term growth through aggressive capacity expansions in ATBS and diversification into Antioxidants and niche specialty chemicals via VAPL and VOPL, targeting a 20-25% revenue growth in FY25.

    Highlights

    7

    • Revenue from operations stood at ₹430 crores, a 14% decline from ₹500 crores in Q1 FY23.

    • EBITDA declined 16% YoY to ₹109 crores, while PAT fell 18% YoY to ₹83 crores.

    • EBITDA margins remained resilient at 28% despite volume headwinds.

    • Revenue decline was driven 90% by lower volumes and only 10% by pricing corrections.

    • ATBS segment faced significant destocking, particularly from the Oil & Gas sector, expected to normalize by H2 FY24.

    • Veeral Additives (VAPL) is currently operating at 25% capacity due to transient demand pressure in the Antioxidant industry.

    • Total Capex of ₹260 crores for Veeral Organics (VOPL) is on track for commissioning by March 2024.

    What Changed2

    vs Q3 FY24

    Tone shiftGood → NeutralRisks discussed3 → 4 (+1)

    Key financials

    Single quarter

    04 metrics
    1. 01Revenue₹430 Cr-14.0%YoY
    2. 02EBITDA₹109 Cr-16.1%YoY
    3. 03PAT₹83 Cr-17.8%YoY
    4. 04EBITDA Margin28%

    Segment breakdown

    Product Revenue Mix (Q1 FY24)
    40% ATBS Revenue Share20% IBB Revenue Share17% Butyl Phenols Revenue Share
    List

    Guidance & targets

    6
    CategoryTargetPriority
    Revenue
    Niche product portfolio revenue
    ₹150-175 crores
    		High
    Revenue
    Veeral Additives (VAPL) Revenue
    ₹150 crores
    		Medium
    Revenue
    Total Revenue Potential (Butyl Phenols + Antioxidants)
    ₹900-1000 crores
    		Medium
    Revenue
    Annual Sales Growth
    20-25%
    		Medium
    Capacity
    ATBS Capacity Expansion
    60,000 metric tons
    		High
    Profitability
    ROCE for new projects
    20%
    		High

    Risks & concerns

    5
    RiskSeverity

    Inventory Destocking

    ATBS destocking in the Oil & Gas sector is expected to continue until October 2023. — Management acknowledged

    medium

    Low Capacity Utilization in Antioxidants

    The AO plant is currently operating at only 25% capacity due to industry-wide demand pressure. — Management acknowledged

    medium

    NCLT Approval Delay

    The amalgamation of Veeral Additives is pending NCLT approval, which has been repeatedly delayed. — Analyst acknowledged

    low

    Margin Dilution from New Products

    Butyl phenols and Antioxidants have lower EBITDA margins (15-20%) compared to the core business (28%+). — Management acknowledged

    medium

    Areas of Evasion(1)

    • Specific details on NCLT merger timeline (admitted lack of visibility).

    Q&A highlights

    3

    “ATBS actually mostly the decline is from the oil and gas sector... they just built up too much inventory... starting April the next six months is just gone in destocking.”

    Explains that the revenue drop is a transient inventory issue rather than a structural demand loss, with recovery expected from October.

    asked by Surya Narayan Patra

    2 min read5 chapters

    Detailed Narrative

    01

    ATBS Destocking and Recovery Timeline

    The primary driver for the Q1 revenue decline was a significant destocking phase in the ATBS segment, particularly from Oil & Gas customers who overstocked in FY23 due to COVID-related freight concerns. Management noted that 90% of the revenue drop was volume-led. They expect this destocking to conclude by October 2023, with demand normalizing in the second half of FY24.

    02

    Strategic Expansion in Antioxidants (VAPL)

    Veeral Additives (VAPL) has commenced commercial production but is currently operating at a low 25% utilization rate due to transient📎 global demand pressure. Despite this, management remains bullish on the segment, citing double backward integration into butyl phenols and isobutylene as a key competitive advantage. They expect VAPL to contribute ₹150 crores in revenue in FY24, doubling in FY25.

    03

    Veeral Organics (VOPL) Capex and Niche Diversification

    The company is investing ₹260 crores in VOPL to manufacture MEHQ, Guaiacol, and Iso Amylene derivatives. These plants are expected to be commissioned by March 2024. Vinati aims for a 25-30% initial market share in these products, leveraging a cost-effective phenol-based manufacturing route to compete with more expensive hydroquinone-based processes.

    04

    Sustainability and Energy Self-Sufficiency

    Sustainability remains a core focus, with 55% of the company's electrical consumption last year met through renewable sources. Vinati recently commissioned 15 MW of solar power and is adding another 11 MW by September 2023. This initiative is designed to reduce energy dependence on conventional sources and lower the company's carbon footprint.

    05

    Financial Outlook and Capital Allocation

    While new product lines like Butyl Phenols and Antioxidants carry lower EBITDA margins (15-20%) than the core business, management emphasizes a 20% ROCE target for all new investments. For FY24, they expect revenue to remain around ₹2000 crores, with a significant 20-25% growth leap projected for FY25 as new capacities and the ATBS segment recover.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.